{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:04:11Z","timestamp":1774343051740,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clineuro.2022.107374","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T02:13:15Z","timestamp":1658196795000},"page":"107374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["COVID-19 vaccination in people with multiple sclerosis, real-life experience"],"prefix":"10.1016","volume":"220","author":[{"given":"Raed","family":"Alroughani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasem","family":"Al-Hashel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathi","family":"Abokalawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malak","family":"AlMojel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Farouk Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2022.107374_bib1","unstructured":"World Health Organization, Novel coronavirus situation report: 99. 28 April 2020. \u3008https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200428-sitrep-99-covid-19. pdf?sfvrsn=119fc381_2\u3009. Accessed 28 Apr 2020."},{"key":"10.1016\/j.clineuro.2022.107374_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2020.08.011","article-title":"The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies","volume":"551","author":"Hosseini","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.clineuro.2022.107374_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10249","key":"10.1016\/j.clineuro.2022.107374_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clineuro.2022.107374_bib5","unstructured":"AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis [WWW Document]. URL. \u3008https:\/\/www.astrazeneca.com\/media-ce ntre\/press releases\/2021\/astrazeneca-us-vaccine-trial-met-primary-endpoint.html\u3009. accessed 3.22.21."},{"key":"10.1016\/j.clineuro.2022.107374_bib6","unstructured":"M. Kuwait, Kuwait COVID-19 Vaccine, 2021; Available from: \u3008https:\/\/ourworldindata.org\/covid-vaccinations?country=OWID_WRL\u3009."},{"issue":"10269","key":"10.1016\/j.clineuro.2022.107374_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clineuro.2022.107374_bib8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.clineuro.2022.107374_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID\u201019 vaccine\u2010readiness for anti\u2010CD20\u2013depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clineuro.2022.107374_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577599","article-title":"Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients","volume":"356","author":"Kelly","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clineuro.2022.107374_bib11","unstructured":"COVID-19 Vaccine Guidance for People Living with MS. \u3008www.nationalmssociety.org\/coronavirus-covid\u3009- 19-information\/multiple-sclerosis-and-coronavirus\/ covid-19-vaccine-guidance (accessed 18 January 2021)."},{"key":"10.1016\/j.clineuro.2022.107374_bib12","unstructured":"COVID-19 vaccination guidance for people with MS 2021 Available from: \u3008https:\/\/www.msaustralia.org.au\/about-ms\/covid-19-and-ms\/\u3009 covid-19-vaccination-guidance-people-ms."},{"key":"10.1016\/j.clineuro.2022.107374_bib13","unstructured":"COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) and MS 2021 Available from: \u3008https:\/\/mssociety.org.il\/en\/covid\u3009 -19-mrna-vaccines-pfizer-biontech-and-moderna-and-ms\/."},{"key":"10.1016\/j.clineuro.2022.107374_bib14","unstructured":"MS, the coronavirus and vaccines \u2013 updated global advice 2021 Available from: \u3008https:\/\/www.msif.org\/news\/2020\/02\/10\/the\u3009- coronavirus-and-ms-what-you-need-to-know\/."},{"key":"10.1016\/j.clineuro.2022.107374_bib15","unstructured":"MS Treatment Guidelines During the Coronavirus pandemic | National MS Society | National Multiple Sclerosis Society [WWW Document]. URL. \u3008https:\/\/www.nationalmssociety.org\/coronavirus-covid-19-information\/multiple-sclerosis-and-coron\u3009 avirus\/ms-treatment-guidelines-during-coronavirus. accessed 3.21.21."},{"key":"10.1016\/j.clineuro.2022.107374_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clineuro.2022.107374_bib17","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2022.107374_bib18","article-title":"mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis","author":"Di Filippo","year":"2021","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.clineuro.2022.107374_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2022.107374_bib20","unstructured":"Food, U., et al., Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials, 2007."},{"key":"10.1016\/j.clineuro.2022.107374_bib21","unstructured":"Covidvax.live : Live COVID-19 Vaccination Tracker - See vaccinations in real time! [Internet]. Covidvax.live. 2021 [cited 2021 Jun 29]. Available from: \u3008https:\/\/covidvax.live\/location\/kwt\u3009."},{"issue":"10267","key":"10.1016\/j.clineuro.2022.107374_bib22","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clineuro.2022.107374_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/ene.15028","article-title":"Safety of the BNT162b2 COVID\u201019 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel","author":"Lotan","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2022.107374_bib24","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2022.107374_bib25","unstructured":"CDC, Possible Side Effects After Getting a COVID-19 Vaccine. Available online at: \u3008https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/expect\/after\u3009. html (accessed June 15, 2021)."},{"issue":"6","key":"10.1016\/j.clineuro.2022.107374_bib26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/practneurol-2020-002527","article-title":"Protecting people with multiple sclerosis through vaccination","volume":"20","author":"Reyes","year":"2020","journal-title":"Pract. Neurol."},{"issue":"25","key":"10.1016\/j.clineuro.2022.107374_bib27","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clineuro.2022.107374_bib28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.vaccine.2018.11.045","article-title":"Causal relationship between immunological re- sponses and adverse reactions following vaccination","volume":"37","author":"Nakayama","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.clineuro.2022.107374_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/22221751.2021.1891002","article-title":"Inflammation-related adverse reac- tions following vaccination potentially indicate a stronger immune response","volume":"10","author":"Zhuang","year":"2021","journal-title":"Emerg. Microbes Infect."},{"issue":"6","key":"10.1016\/j.clineuro.2022.107374_bib30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-016-8263-4","article-title":"Vaccines and multiple sclerosis: a sys- tematic review","volume":"264","author":"Mailand","year":"2017","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.clineuro.2022.107374_bib31","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","article-title":"Immunizations and risk of multi- ple sclerosis: systematic review and meta-analysis","volume":"258","author":"Farez","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2022.107374_bib32","first-page":"12","article-title":"Severe multiple sclerosis relapse after COVID-19 vaccination: a case report","author":"Maniscalco","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2022.107374_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103028","article-title":"Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis","volume":"52","author":"Allen-Philbey","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.clineuro.2022.107374_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clineuro.2022.107374_bib35","unstructured":"Web Page: YouGov, 2020, How many Britons are willing to take a coronavirus vaccine? Access date: 3 February 2021. \u3008https:\/\/yougov.co.uk\/topics\/health\/articles-repor\u3009 ts\/2020\/11\/16\/how-many-britons-are-willing-take-coronavirus-vacc."},{"issue":"4","key":"10.1016\/j.clineuro.2022.107374_bib36","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/S2665-9913(21)00037-0","article-title":"Perspective of patients with autoimmune diseases on COVID-19 vaccination","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.clineuro.2022.107374_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102880","article-title":"Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients","volume":"51","author":"Serrazina","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2022.107374_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102788","article-title":"Willingness to obtain COVID- 19 vaccination in adults with multiple sclerosis in the United States","volume":"49","author":"Ehde","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.clineuro.2022.107374_bib39","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000991","article-title":"Vaccine hesitancy in patients with multiple sclerosis: preparing for the SARS- CoV-2 vaccination challenge","volume":"8","author":"Diem","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflam"},{"issue":"2","key":"10.1016\/j.clineuro.2022.107374_bib40","article-title":"COVID-19 vaccination willingness among people with multiple sclerosis","volume":"7","author":"Xiang","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"34","key":"10.1016\/j.clineuro.2022.107374_bib41","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Vaccine hesitancy: definition, scope and determinants","volume":"33","author":"MacDonald","year":"2015","journal-title":"Vaccine"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846722002554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846722002554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:42:58Z","timestamp":1759588978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846722002554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":41,"alternative-id":["S0303846722002554"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2022.107374","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccination in people with multiple sclerosis, real-life experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2022.107374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107374"}}